EP0778948A1 - Predictive test for hepatitis-b resistance - Google Patents
Predictive test for hepatitis-b resistanceInfo
- Publication number
- EP0778948A1 EP0778948A1 EP95930612A EP95930612A EP0778948A1 EP 0778948 A1 EP0778948 A1 EP 0778948A1 EP 95930612 A EP95930612 A EP 95930612A EP 95930612 A EP95930612 A EP 95930612A EP 0778948 A1 EP0778948 A1 EP 0778948A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hepatitis
- hla
- drb1
- hbv
- class
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000012360 testing method Methods 0.000 title description 5
- 208000006454 hepatitis Diseases 0.000 title description 3
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 16
- 230000028993 immune response Effects 0.000 claims abstract description 12
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims description 11
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims description 11
- 102210005807 HLA-DRB1*1301 Human genes 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 206010059193 Acute hepatitis B Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims 4
- 238000011321 prophylaxis Methods 0.000 claims 3
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 31
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 31
- 102000054766 genetic haplotypes Human genes 0.000 description 30
- 208000015181 infectious disease Diseases 0.000 description 24
- 239000000427 antigen Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 230000002085 persistent effect Effects 0.000 description 10
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 7
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 102000043131 MHC class II family Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 201000004792 malaria Diseases 0.000 description 4
- 101150034979 DRB3 gene Proteins 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- 101100278514 Oryza sativa subsp. japonica DRB2 gene Proteins 0.000 description 3
- 208000037581 Persistent Infection Diseases 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 230000009696 proliferative response Effects 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 208000020545 Exposure to communicable disease Diseases 0.000 description 1
- 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 description 1
- 108010061311 HLA-DRB3 Chains Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 235000013382 Morus laevigata Nutrition 0.000 description 1
- 244000278455 Morus laevigata Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 208000037628 acute hepatitis B virus infection Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000034998 susceptibility to hepatitis B virus Diseases 0.000 description 1
- 208000037369 susceptibility to malaria Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to a novel method of predicting resistance to Hepatitis B, peptides useful in modifying immune response to Hepatitis B, vaccines against Hepatitis B and methods of treating Hepatitis B.
- HVB hepatitis B virus
- Persistent HBV infection predisposes the host to chronic liver disease and hepatocellular carcinoma
- HBV infection does not appear to be determined by variations in virulence of the virus, and the course of disease may be influenced by the host immune response. Although a proportion of patients with persistent infection have specific immunodeficiency states such as HIV (Krosgaard, K. et al , Hepatology, 7: 37-41, 1987) or agamma-globulinaemia (Hermaszewski, R. A. et al , Q. J. Med. , 86(1): 31-42, 1993), the majority are not otherwise immunocompromised. In West Africa, HBV is transmitted via a horizontal route with young children (under 10 years) acquiring the infection from older siblings or playmates (Marinier, E. et al , West Africa J.
- HBV related hepatocellular 15 carcinoma is the leading cause of male mortality in adults of working age in The Gambia (Ryder et al, Am. J. Epidemiol . , supra; and Kiire, C. F., Vaccine, 8: 5107- 112, 1990) .
- class I or class II molecules 25 specific class I or class II molecules.
- CTL cytotoxic T lymphocytes
- DRB1*1302 is associated with a reduced risk of cerebral malaria in Gambian children, which may relate to the high frequency of the DRB1*1302-DRB3*0301-DQA1*0102-DQB1*0501 and DRB1*1302-DRB3*0301-DQA1*0102-DQB1*0604 haplotypes in this population (Lepage, V. et al , supra) .
- the combined haplotype frequency in North Europeans is 4.4% compared with 16.4% in The Gambia (Hill, A. et al , Nature, 352(6336), 595-600, 1991). Malaria and HBV are both important causes of premature mortality in West Africa.
- HBV HBV related mortalities are common during working life. If recovery from HBV infection were also linked to DRB1*1302, in addition to malaria, HBV would confer a selective advantage on individuals carrying the DRB1*1302 haplotypes in The Gambia.
- DRw6 which is the serological supertype of DRB1*1302 and DRB1*1301, was identified in two previous studies as potentially protective against persistent HBV infection. Van Hattum et al found DRw6 nearly twice as frequently in North European patients who cleared HBV than in those who failed to eliminate the virus (Van-Hattum, J. et al , supra) . In a study of factors influencing the response of chronic HBV infection to interferon therapy, we found that DRw6 is associated with a favourable response (Scully, L. et al , Hepatology, 12: 1111-17, 1990). However, both these studies were too small to reach statistical significance.
- the present invention provides a method of identifying resistance to Hepatitis B infection which comprises the step of identifying the presence of HLA- DRB1*1302. Suitably identification is carried out on a sample of blood.
- the invention provides a convenient method of predicting Hepatitis B resistance in any given individual and hence also allows for predictions to be made concerning the outcome of Hepatitis B infection in individual patients.
- the method of the present invention further comprises the step of identifying the presence of HLA-DRB1*1301. Again, this is suitably carried out by analysing a blood sample.
- HLA- DRB1*1302 and/or HLA-DRB1*1301 is/are associated with resistance to Hepatitis B
- the present invention also provides one or more peptides capable of binding to HLA- DRB1*1302 and/or HLA-DRB1*1301.
- Such peptides can be used to modify the ability of HLA-DRB1*1302 and/or HLA- DRB1*1301 to elicit an immune response.
- Such an approach would be useful in immunisation against HBV infection, and in DRB1*1302 and *1301 individuals, who had become persistently infected, would facilitate recovery
- binding of the one or more modified peptides will result in a reduced immune response. This is particularly advantageous in treating conditions such as fulminant Hepatitis B.
- the present invention provides a peptide capable of modifying the ability of an HLA to elicit an immune response in response to a Hepatitis B antigen.
- the peptide is one derived from a Hepatitis B antigen.
- the peptide can consist only of a particular region known to bind to a particular HLA molecule.
- a synthetic peptide could be constructed consisting of a binding region and other, non-binding regions.
- the peptides can be administered in the form of a pharmaceutical formulation, eg. as an intravenous formulation.
- a pharmaceutical formulation comprising one or more peptides capable of binding to HLA-DRB1*1302 and/or HLA-DRB1*1301, together with one or more pharmaceutically acceptable carriers and/or excipients.
- the invention also provides a vaccine against Hepatitis B comprising one or more peptides capable of binding to HLA-DRB1*1302 and/or HLA-DRB1*1301.
- the peptides of the invention also provide other methods of treating Hepatitis B.
- antigen specific lymphocytes can be generated in vi tro using a peptide of the invention. These can then be administered to a patient suffering from Hepatitis B.
- the present invention therefore also provides a composition comprising lymphocytes wherein the lymphocytes have been exposed to one or more peptides of the invention.
- a method of treating Hepatitis B is also provided which comprises the step of administering such a composition to a subject.
- lymphocytes will either be from the subject being treated or from another with a similar HLA type.
- FIG T RE 1 shows Hepatitis B exposure and HBsAg carriage rise with age during childhood.
- FIGURE 2 shows the frequencies of HLA class I serotypes for each group of children and adults.
- FIGURE 3 shows the class II haplotypes for the children.
- FIGURE 4 shows the class II haplotypes for the adults
- FIGURE 5 shows the differential analysis of risk for individual DRB1*1302 Haplotypoes.
- the subjects were all Gambians living in the area surrounding the capital, Banjul, which is in the western coastal region. Two different populations were recruited for the two stages of the study between 1988 and 1990. In the first stage, children up to 10 years were recruited at the Royal Victoria Hospital, Banjul, and the Medical Research Council Hospital, Fajara, where they had been seen for a variety of conditions unrelated to HBV. The adult population was recruited from healthy male blood donors. Both populations had previously been studied as part of a case-control study of susceptibility to malaria (Hill, A. et al , supra) .
- Group C who had persistent HBV infection, were Anti-HBc positive and HBsAg positive.
- Patients in Group C who had IgM antibodies to HBV core antigen, were excluded from the analysis.
- Individuals who had received vaccination against HBV ( ⁇ 10%) fell into group A and were not therefore included in the analysis of HLA frequencies.
- In the Adult population there were a total of 260 subjects: 25 in Group A, 195 in Group B and 41 in Group C. The very small number of individuals with HIV antibodies ( ⁇ 1%) were excluded.
- Plasma samples were taken from all subjects and stored at -20°C.
- Anti-HBc, Anti-HBc(IgM) and HBsAg status and anti-HBs antibody concentration were determined by ELISA according to the manufacturers instructions (Boehringer Mannheim, Kunststoff, Germany) .
- Anti-HIV status was determined by Wellcozyme ELISA (Wellcome, Beckenham, UK) and positive results confirmed by Western Blot.
- HLA Tvpin ⁇ Class I serotyping was performed on approximately half the subjects in each population.
- Serological MHC class I types were determined by standard microlymphocytotoxicity assays using 180 well characterised antisera on fresh or cryopreserved cells (Rood, J., Van, Manual of Tissue Typing Technisques, Bethesda, Maryland : National Insti tutes of Heal th, 104- 105, 1979) .
- MHC Class II typing was performed by restriction fragment length polymorphism analysis, as previously described, using the restriction enzymes Tagl and BamHl (Hill et al , supra; and Hill, A. et al , Proc. Na tl . Acad. Sci .
- HLA class II haplotypes were initially determined using the restriction enzyme Tagl to define restriction fragment length polymorphism (RFLP) haplotype (Hill, A. et al , Proc . Natl . Acad . Sci . USA, supra) .
- RFLP restriction fragment length polymorphism
- the RFLP pattern 25-1 which corresponds with the class II haplotypes DRB1*1302-DRB3*0301-DQA1*0102-DQB1*0501 (DRwl3/DQw5) and DRB1*1302-DRB3*0301-DQA1*0102-DQB1*0604 (DRwl3/DQw6) , was found in 26.6% of the children who had cleared HBV infection (Group B) and in 16.2% of the children with persistent HBV infection (Group C) (relative risk 0.53 [95% CI 0.32 - 0.90], p - 0.012), and is therefore associated with a protective effect against persistent HBV carriage.
- the study clearly shows that the RFLP defined haplotype 25-1 is associated with the ability to clear HBV after infection.
- the 25-1 haplotype represents two MHC class II haplotypes, DRB1*1302-DRB3*0301-DQA1*0102- DQB1*0501 and DRB1*1302-DRB3*0301-DQA1*0102-DQB1*0604. Further analysis has shown that the two DRB1*1302 haplotypes are both associated with HBV clearance, and it is therefore probable that one or both of the shared HLA- DR alleles are responsible for this association.
- HLA- DRB1*1302 is only found on the 25-1 RFLP haplotypes, whereas HLA-DRB3*0301 is also found on other RFLP haplotypes in The Gambia. Furthermore, the product of DRB1*1302 is expressed at a higher level than the DRB3 locus product and may thus be of greater functional importance. We conclude that, on the 25-1 haplotype, the DRB1*1302 seems most likely to be of importance in viral clearance.
- the RFLP haplotype 13-2 which corresponds to the class II haplotype DRB1*1301- DRB3*0101-DQA1*0103-DQB1*0603, is also associated with a degree of resistance to HBV persistence in the population, as suggested by the data on persistently infected children.
- the DRB1 allele of this haplotype, DRB1*1301 differs from HLA-DRB1*1302 by just a single amino acid substitution.
- HBV-specific CD4+ helper activity as judged by the proliferative response to HBcAg and HsAg, is markedly reduced in patients with persistent infection in comparison to patients with acute self limiting infection (Ferrari, C. et al , J. Immunol . , supra).
- the class II molecule is considered to be critical in the development of CD4+ helper T cell responses and therefore differential ability of class II molecules to present antigens may manifest as variability in the level of CD4+ help. This is consistent with the detection of a specific class II association with HBV clearance.
- HLA B8, SC01, DR3 in Caucasians (Egea, E. et al, J. Exp .
- HLA-DRB1*1302 HLA-DRB1*1302
- HBV clearance a higher titre of anti-HBs antibody in individuals with this HLA allele.
- levels of anti-HBs antibody in adults who had eliminated HBV were not higher amongst those with the HLA-DRB1*1302 allele, suggesting that the provision of extra "help" for the generation of this antibody response is not the critical mechanism in enhanced HBV clearance in carriers of HLA- DRB1*1302.
- HBV infected hepatocytes can be recognised and destroyed by HLA class I restricted CTL (Mondelli, M. et al , J. Immunol . , 129(6) : 2773-78, 1982; and Pignattelli, M. et al , J. Hepatol . , 4: 15-21, 1987) .
- HLA class I restricted CTL Mondelli, M. et al , J. Immunol . , 129(6) : 2773-78, 1982; and Pignattelli, M. et al , J. Hepatol . , 4: 15-21, 1987.
- HBV antigens are presented with comparable efficiency by all the class I molecules found in high frequency in The Gambia.
- HBV- specific CTL are not readily detectable, which may indicate that the numbers are low or that the CTLs are inactive.
- DRB1*1302 appears to be associated with a potent protective effect against three important infectious pathogens, but it is not clear how it might exert this effect.
- Malaria, HBV and HPV are complex pathogens in which there must be hundreds of potential T cell epitopes with variable MHC restriction elements.
- the occurrence of an MHC association in any of these diseases suggests that there may only be a small number of epitopes to It is therefore conceivable that polymorphisms of the MHC class I and II loci contribute to the variability in outcome from HBV infection.which a protective immune response is mounted.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Methods of identifying resistance to Hepatitis B infection are disclosed, as well as peptides capable of modifying immune response and methods of treating Hepatitis B.
Description
PREDICTIVE TEST FOR HEPATITIS-B RESISTANCE
The present invention relates to a novel method of predicting resistance to Hepatitis B, peptides useful in modifying immune response to Hepatitis B, vaccines against Hepatitis B and methods of treating Hepatitis B.
Infection with hepatitis B virus (HVB) may result in a number of disease states ranging from fulminant hepatitis with liver failure to asymptomatic persistent carriage. Most patients will suffer an acute hepatitis during which the virus is eliminated. About 5% of patients in North America and Europe fail to eliminate the virus, whereas in West Africa up to 15% of infected patients fail to clear HVB (Ryder, R. W. et al , Lancet, ii(8400): 449-52
1984) . Persistent HBV infection predisposes the host to chronic liver disease and hepatocellular carcinoma
(Beasley, R. et al , Lancet, ii, 1159-63, 1981), which is a common cause of death in adults of working age in West Africa (Ryder, R. W. et al . , Am. J. Epidemiol . , 136(9): 1122-31, 1992) .
The outcome of HBV infection does not appear to be determined by variations in virulence of the virus, and the course of disease may be influenced by the host immune response. Although a proportion of patients with persistent infection have specific immunodeficiency states such as HIV (Krosgaard, K. et al , Hepatology, 7: 37-41, 1987) or agamma-globulinaemia (Hermaszewski, R. A. et al , Q. J. Med. , 86(1): 31-42, 1993), the majority are not otherwise immunocompromised.
In West Africa, HBV is transmitted via a horizontal route with young children (under 10 years) acquiring the infection from older siblings or playmates (Marinier, E. et al , West Africa J. Pediatr., 106(5): 843-9, 1985; and Botha, J. F. et al , Lancet, i(8388), 1210-2, 1984) . Vertical transmission, as seen in the Far East, is rare, so that immaturity of the immune system and the tolerogenic effects of trans-placental HBV 'e' antigen (HBeAg) transfer are unlikely to affect the outcome of ι n infection. Epidemiological studies have shown that about 80% of the adult population have been infected with HBV, and that the persistent carriage rate, as determined by HBV surface antigen carriage, is around 12-15% (Ryder et al , supra) . Death from HBV related hepatocellular 15 carcinoma is the leading cause of male mortality in adults of working age in The Gambia (Ryder et al, Am. J. Epidemiol . , supra; and Kiire, C. F., Vaccine, 8: 5107- 112, 1990) .
20 Recognition of foreign antigens by T lymphocytes is achieved through the presentation of antigenic peptides in the groove of MHC encoded H A molecules. Such immunological responses are MHC restricted, meaning that foreign antigens are only recognised when presented by
25 specific class I or class II molecules. In patients with acute hepatitis B, class I restricted cytotoxic T lymphocytes (CTL) are present in the peripheral blood which recognise the nucleocapsid and envelope antigens of HBV (Bertoletti, A. et al , Proc . Na tl . Acad. Sci , USA,
30 88(23): 10445-9, 1991) . In addition there is a strong class II restricted proliferative response to the nucleocapsid antigens (Ferrari, C. et al , J. Clin .
Invest, 88: 214-22, 1991). CD4+ T helper cell responses to the nucleocapsid and envelope antigens of the virus are required to support anti-HBe and anti-HBs antibody development (Milich, D. et al , Na ture, 319: 547-9, 1987) . In patients with chronic HBV infection, CTL are not detectable and the proliferative response is absent or significantly reduced (Ferrari, C. et al , J. Immunol . , 145(10): 3442-9, 1990; and Tsai, S. et al , J. Clin . Invest . , 89: 87-96 1992).
Several studies have examined the role of MHC phenotype in the outcome of HBV infection without reaching a firm conclusion (Van-Hattum, J. et al , Hepatology, 7(1): 11- 14, 1987; Forzani, B. et al, Hepatology, 4: 1107-10, 1984; Lepage, V. e al, Tissue Antigens , 18: 105-7, 1981; and Kaslow, R. and Shaw, S., Epidemiol . Rev. 3: 90-114, 1981) . However, the majority of these studies have been of a size that could only detect a very strong association between MHC phenotype and disease state. Furthermore the sensitivity of these studies has been compromised by using serologically defined MHC class II typing methods which may assign a large number of alleles to the same serological specificity.
DRB1*1302 is associated with a reduced risk of cerebral malaria in Gambian children, which may relate to the high frequency of the DRB1*1302-DRB3*0301-DQA1*0102-DQB1*0501 and DRB1*1302-DRB3*0301-DQA1*0102-DQB1*0604 haplotypes in this population (Lepage, V. et al , supra) . The combined haplotype frequency in North Europeans is 4.4% compared with 16.4% in The Gambia (Hill, A. et al , Nature, 352(6336), 595-600, 1991). Malaria and HBV are both
important causes of premature mortality in West Africa. However, whereas severe malaria has a high mortality rate in children under 5, HBV related mortalities are common during working life. If recovery from HBV infection were also linked to DRB1*1302, in addition to malaria, HBV would confer a selective advantage on individuals carrying the DRB1*1302 haplotypes in The Gambia.
A recent study has shown a protective effect against human papilloma virus (HPV) related cervical carcinoma associated with DRB1*1302 and DRB1*1301 (Apple, R. J. et al , Nature Genetics, 6(2): 157-162, 1994) .
DRw6, which is the serological supertype of DRB1*1302 and DRB1*1301, was identified in two previous studies as potentially protective against persistent HBV infection. Van Hattum et al found DRw6 nearly twice as frequently in North European patients who cleared HBV than in those who failed to eliminate the virus (Van-Hattum, J. et al , supra) . In a study of factors influencing the response of chronic HBV infection to interferon therapy, we found that DRw6 is associated with a favourable response (Scully, L. et al , Hepatology, 12: 1111-17, 1990). However, both these studies were too small to reach statistical significance.
It has now been found that the presence of certain HLA molecules confers resistance to infection by Hepatitis B.
Accordingly, the present invention provides a method of identifying resistance to Hepatitis B infection which comprises the step of identifying the presence of HLA-
DRB1*1302. Suitably identification is carried out on a sample of blood. Thus, the invention provides a convenient method of predicting Hepatitis B resistance in any given individual and hence also allows for predictions to be made concerning the outcome of Hepatitis B infection in individual patients.
In one embodiment the method of the present invention further comprises the step of identifying the presence of HLA-DRB1*1301. Again, this is suitably carried out by analysing a blood sample.
Furthermore, in view of the recognition that HLA- DRB1*1302 and/or HLA-DRB1*1301 is/are associated with resistance to Hepatitis B, it is possible to modify the immune response of an individual by means of peptides which bind to one or both of those HLA molecules. In another aspect therefore, the present invention also provides one or more peptides capable of binding to HLA- DRB1*1302 and/or HLA-DRB1*1301. Such peptides can be used to modify the ability of HLA-DRB1*1302 and/or HLA- DRB1*1301 to elicit an immune response. Such an approach would be useful in immunisation against HBV infection, and in DRB1*1302 and *1301 individuals, who had become persistently infected, would facilitate recovery
(therapeutic immunisation) . In a preferred embodiment, binding of the one or more modified peptides will result in a reduced immune response. This is particularly advantageous in treating conditions such as fulminant Hepatitis B.
More generally the present invention provides a peptide
capable of modifying the ability of an HLA to elicit an immune response in response to a Hepatitis B antigen.
Preferably the peptide is one derived from a Hepatitis B antigen. For example, the peptide can consist only of a particular region known to bind to a particular HLA molecule. Alternatively, a synthetic peptide could be constructed consisting of a binding region and other, non-binding regions.
The peptides can be administered in the form of a pharmaceutical formulation, eg. as an intravenous formulation. Thus, in another aspect the invention provides a pharmaceutical formulation comprising one or more peptides capable of binding to HLA-DRB1*1302 and/or HLA-DRB1*1301, together with one or more pharmaceutically acceptable carriers and/or excipients.
In addition, such peptides can be used in the production of a vaccine against Hepatitis B. Accordingly, the invention also provides a vaccine against Hepatitis B comprising one or more peptides capable of binding to HLA-DRB1*1302 and/or HLA-DRB1*1301.
The peptides of the invention also provide other methods of treating Hepatitis B. For instance, antigen specific lymphocytes can be generated in vi tro using a peptide of the invention. These can then be administered to a patient suffering from Hepatitis B. The present invention therefore also provides a composition comprising lymphocytes wherein the lymphocytes have been exposed to one or more peptides of the invention. A method of treating Hepatitis B is also provided which comprises the step of administering such a composition to a subject.
In general the lymphocytes will either be from the
subject being treated or from another with a similar HLA type.
The invention will now be described by means of the following example which should not be construed as limiting the scope of the invention in any way.
The example refers to the figures wherein:
FIGTRE 1; shows Hepatitis B exposure and HBsAg carriage rise with age during childhood.
FIGURE 2; shows the frequencies of HLA class I serotypes for each group of children and adults.
FIGURE 3; shows the class II haplotypes for the children.
FIGURE 4; shows the class II haplotypes for the adults;and
FIGURE 5; shows the differential analysis of risk for individual DRB1*1302 Haplotypoes.
EXAMPLE 1
Study Populations
The subjects were all Gambians living in the area surrounding the capital, Banjul, which is in the western coastal region. Two different populations were recruited for the two stages of the study between 1988 and 1990. In the first stage, children up to 10 years were
recruited at the Royal Victoria Hospital, Banjul, and the Medical Research Council Hospital, Fajara, where they had been seen for a variety of conditions unrelated to HBV. The adult population was recruited from healthy male blood donors. Both populations had previously been studied as part of a case-control study of susceptibility to malaria (Hill, A. et al , supra) .
In both stages, subjects were divided into groups according to serological tests for HBV. Group A, who had never been exposed to HBV, were anti-HBV core antibody
(anti-HBe) negative. Group B, who had spontaneously recovered from HBV infection, were Anti-HBc positive and
HBV surface antigen (HBsAg) negative. Group C, who had persistent HBV infection, were Anti-HBc positive and HBsAg positive. Patients in Group C, who had IgM antibodies to HBV core antigen, were excluded from the analysis. Individuals who had received vaccination against HBV (<10%) fell into group A and were not therefore included in the analysis of HLA frequencies. There were a total of 1344 children; 891 in Group A, 218 in Group B and 185 in Group C. In the Adult population there were a total of 260 subjects: 25 in Group A, 195 in Group B and 41 in Group C. The very small number of individuals with HIV antibodies (<1%) were excluded.
Seroloσical Testing
Plasma samples were taken from all subjects and stored at -20°C. Anti-HBc, Anti-HBc(IgM) and HBsAg status and anti-HBs antibody concentration were determined by ELISA according to the manufacturers instructions (Boehringer Mannheim, Munich, Germany) . Anti-HIV status was
determined by Wellcozyme ELISA (Wellcome, Beckenham, UK) and positive results confirmed by Western Blot.
HLA Tvpinσ Class I serotyping was performed on approximately half the subjects in each population. Serological MHC class I types were determined by standard microlymphocytotoxicity assays using 180 well characterised antisera on fresh or cryopreserved cells (Rood, J., Van, Manual of Tissue Typing Technisques, Bethesda, Maryland : National Insti tutes of Heal th, 104- 105, 1979) . MHC Class II typing was performed by restriction fragment length polymorphism analysis, as previously described, using the restriction enzymes Tagl and BamHl (Hill et al , supra; and Hill, A. et al , Proc. Na tl . Acad. Sci . USA, 89: 227-81, 1992). This was supplemented, where necessary, by polymerase chain reaction amplification and sequence specific oligonucleotide blotting (Hill et al , supra; and Hill, A. et al , Proc . Natl . Acad. Sci . USA, 89, 227-81, 1992). All patients were assigned a class II type.
Statistical Analysis
Comparisons of phenotype (RFLP-defined haplotype for class II) frequencies between groups B and C were made for 23 HLA class I antigens and 10 class II haplotypes using the χ2 test. When multiple comparisons are made concurrently, an apparently significant association may arise by chance. In order to avoid this type of error, we adopted a two stage strategy: multiple comparisons were made in the first population (children) , and the second population (adults) was then used to test a single
hypothesis (Hill, A., J. RCP. , 26(1): 11-16, 1992) . Relative risk was calculated by the crude odds ratio and is given with a 95% confidence interval. As there is a mixed ethnic composition in The Gambia (Hill, A. eϋ al , Proc. Natl . Acad. Sci . USA, supra), Mantel-Haenszel tests were performed to assess a possible confounding effect of ethnic origin. Anti-HBs concentration were compared in the adult population between subjects with HLA-DRB1*1302 and those without, using the unpaired t test.
Results
453 of the 1344 children recruited (33.7%) were anti-HBe positive and, of these, 185 (13.8%) were HBsAg positive and anti-HBe (IgM) negative. 218 (16.2%) children were anti-HBe (total) positive, anti-HBe(IgM) negative and HBsAg negative. The rise with age of anti-HBe and HBsAg carriage are shown in Figure 1. 260 adults were recruited to the study, of which 235 (90.4%) were anti- HBe positive and 41 (15.8%) HBsAg positive. The frequencies of HLA class I serotypes and class II haplotypes for each group of children are shown in Tables 1, 2 and 3 respectively.
Possible associations between the HLA class I antigens, HLA-B50 and HLA-Cwl and persistent HBsAg carriage were suggested by the data from the study of children (Table 1) . However, these findings were not supported by the data from the adults studied (Table 1) . Hence, no class I phenotype was significantly associated with HBV clearance.
HLA class II haplotypes were initially determined using
the restriction enzyme Tagl to define restriction fragment length polymorphism (RFLP) haplotype (Hill, A. et al , Proc . Natl . Acad . Sci . USA, supra) . The RFLP pattern 25-1, which corresponds with the class II haplotypes DRB1*1302-DRB3*0301-DQA1*0102-DQB1*0501 (DRwl3/DQw5) and DRB1*1302-DRB3*0301-DQA1*0102-DQB1*0604 (DRwl3/DQw6) , was found in 26.6% of the children who had cleared HBV infection (Group B) and in 16.2% of the children with persistent HBV infection (Group C) (relative risk 0.53 [95% CI 0.32 - 0.90], p - 0.012), and is therefore associated with a protective effect against persistent HBV carriage. The RFLP haplotype 13-2, which corresponds to the class II haplotype DRB1*1301- DRB3*0101-DQA1*0103-DQB1*0603, was also found at a significantly reduced frequency in persistently infected children (p = 0.037). No other haplotype showed a significant frequency alteration. We therefore proceeded to analyse these two possible associations in the adult population. The HLA-DRB1*1302 haplotypes were found in 50 of 195 (25.6%) adult subjects from Group B (cleared infection) and 3 of 40 (7.5%) patients with persistent infection (relative risk 0.24, [95% confidence interval 0.04 to 0.80], p = 0.012). After stratification by ethnic origin, the Mantel-Haenszel weighted relative risk was 0.23 [95% CI 0.05 - 0.83], p = 0.022; therefore, a significant confounding effect of ethnic origin was excluded. The possible association with HLA-DRB1*1301 was not confirmed by the data on the adult population.
Subjects with the 25-1 haplotypes from both populations were further subdivided into the DQw5 or DQw6 haplotypes. Relative risk and 95% confidence intervals were
calculated for both haplotypes and are compared in Table 4. Elimination of HBV is associated with both
haplotypes, which suggests that protection from persistent HBV carriage is associated with the HLA-DR molecule bearing DRB1*1302.
In 25 adults with DRB1*1302 (mean age 28.6), the mean anti-HBs concentration was 15.5 iu/L (s.d. 41.5), and in 25 adults without DRB1*1302 (mean age 32.2) the mean anti-HBs antibody concentration was 22.3 (s.d. 48.5); p = 0.598.
Discussion This is the first large HLA association study of HBV infection which has incorporated molecular class II analysis. The study clearly shows that the RFLP defined haplotype 25-1 is associated with the ability to clear HBV after infection. The 25-1 haplotype represents two MHC class II haplotypes, DRB1*1302-DRB3*0301-DQA1*0102- DQB1*0501 and DRB1*1302-DRB3*0301-DQA1*0102-DQB1*0604. Further analysis has shown that the two DRB1*1302 haplotypes are both associated with HBV clearance, and it is therefore probable that one or both of the shared HLA- DR alleles are responsible for this association. HLA- DRB1*1302 is only found on the 25-1 RFLP haplotypes, whereas HLA-DRB3*0301 is also found on other RFLP haplotypes in The Gambia. Furthermore, the product of DRB1*1302 is expressed at a higher level than the DRB3 locus product and may thus be of greater functional importance. We conclude that, on the 25-1 haplotype, the DRB1*1302 seems most likely to be of importance in viral
clearance. It is possible that the RFLP haplotype 13-2, which corresponds to the class II haplotype DRB1*1301- DRB3*0101-DQA1*0103-DQB1*0603, is also associated with a degree of resistance to HBV persistence in the population, as suggested by the data on persistently infected children. Incidently, the DRB1 allele of this haplotype, DRB1*1301, differs from HLA-DRB1*1302 by just a single amino acid substitution.
HBV-specific CD4+ helper activity, as judged by the proliferative response to HBcAg and HsAg, is markedly reduced in patients with persistent infection in comparison to patients with acute self limiting infection (Ferrari, C. et al , J. Immunol . , supra). Through its role in antigen presentation, the class II molecule is considered to be critical in the development of CD4+ helper T cell responses and therefore differential ability of class II molecules to present antigens may manifest as variability in the level of CD4+ help. This is consistent with the detection of a specific class II association with HBV clearance. We infer that, in patients with persistent HBV infection, failure to develop anti-HBe and anti-HBs, and the failure to develop sufficient numbers of active HBV-specific CTL, are at least in part related to the lack of CD4+ help mediated by class II molecules with relatively poor antigen presenting ability.
Failure to develop reasonable levels of anti-HBs following vaccination is associated with the haplotype
HLA B8, SC01, DR3 in Caucasians (Egea, E. et al, J. Exp .
Med. , 173 (3): 531-8, 1991). It seemed possible that the
association of HLA-DRB1*1302 with HBV clearance might be reflected in a higher titre of anti-HBs antibody in individuals with this HLA allele. However, levels of anti-HBs antibody in adults who had eliminated HBV were not higher amongst those with the HLA-DRB1*1302 allele, suggesting that the provision of extra "help" for the generation of this antibody response is not the critical mechanism in enhanced HBV clearance in carriers of HLA- DRB1*1302.
HBV infected hepatocytes can be recognised and destroyed by HLA class I restricted CTL (Mondelli, M. et al , J. Immunol . , 129(6) : 2773-78, 1982; and Pignattelli, M. et al , J. Hepatol . , 4: 15-21, 1987) . The absence of a strong HLA class I association with HBV clearance may imply that HBV antigens are presented with comparable efficiency by all the class I molecules found in high frequency in The Gambia. In chro ic HBV infection, HBV- specific CTL are not readily detectable, which may indicate that the numbers are low or that the CTLs are inactive. One interpretation of our finding of an HLA class II association with HBV clearance is that CTL activity requires strong help from CD4+ T helper cells, the level of which is determined by HLA class II polymorphism (Nonacs, R. et al , J. Exp. Med. , 176: 519- 29, 1992) .
DRB1*1302 appears to be associated with a potent protective effect against three important infectious pathogens, but it is not clear how it might exert this effect. Malaria, HBV and HPV are complex pathogens in which there must be hundreds of potential T cell epitopes
with variable MHC restriction elements. The occurrence of an MHC association in any of these diseases suggests that there may only be a small number of epitopes to It is therefore conceivable that polymorphisms of the MHC class I and II loci contribute to the variability in outcome from HBV infection.which a protective immune response is mounted.
Claims
1. A method of identifying resistance to Hepatitis B infection which comprises the step of identifying the presence of HLA-DRB1*1302.
2. A method as claimed in claim 1 which further comprises the step of identifying the presence of HLA- DRB1*1301.
3. A method as claimed in claim 1 or claim 2 wherein identification is carried out on a blood sample.
4. A method of predicting the outcome of Hepatitis B infection in a patient which comprises identification of the patient's tissue type.
5. A peptide capable of binding to HLA-DRB1*1302 and/or HLA-DRB1*1301.
6. A peptide as claimed in claim 4 capable of modifying the ability of HLA-DRB1*1302 and/or HLA-DRB1*1301 to elicit an immune response.
7. A peptide capable of modifying the ability of an HLA to elicit an immune response in response to a Hepatitis B antigen.
8. A peptide as claimed in any one of claims 5 to 7 which is derived from a Hepatitis B antigen.
9. A pharmaceutical formulation comprising a peptide as defined in any one of claims 5 to 8, together with one or more pharmaceutically acceptable carriers and/or excipients.
5 10. A pharmaceutical formulation as claimed in claim 9 which is for intravenous administration.
11. A vaccine against Hepatitis B comprising one or more peptides as defined in any one of claims 5 to 8.
1 -_ nU
12. A composition comprising lymphocytes which have been treated with one or more peptides as defined in any one of claims 5 to 8.
15 13. A method of modifying the immune response of a subject to Hepatitis B which comprises the step of administering to the subject one or more peptides as defined in any one of claims 5 to 8.
0 14. A method as claimed in claim 13 wherein the immune response is reduced.
15. A method as claimed in claim 14 which is used to treat fulminant Hepatitis B. 5
16. A method for the treatment or prophylaxis of Hepatitis B which comprises the step of administering to a subject one or more peptides any one of claims 5 to 8.
0 17. A method for the treatment or prophylaxis of Hepatitis B which comprises the step of administering to a subject a pharmaceutical formulation as defined in claim 9 or claim 10.
18. A method for the treatment or prophylaxis of Hepatitis B which comprises the step of administering to a subject a vaccine as defined in claim li.
19. A method for the treatment or prophlylaxis of Hepatitis B which compries the step of administering to a subject a composition as defined in claim 12.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9417850A GB9417850D0 (en) | 1994-09-02 | 1994-09-02 | Predictive test |
GB9417850 | 1994-09-02 | ||
PCT/GB1995/002067 WO1996007915A1 (en) | 1994-09-02 | 1995-09-01 | Predictive test for hepatitis-b resistance |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0778948A1 true EP0778948A1 (en) | 1997-06-18 |
Family
ID=10760853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95930612A Withdrawn EP0778948A1 (en) | 1994-09-02 | 1995-09-01 | Predictive test for hepatitis-b resistance |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0778948A1 (en) |
JP (1) | JPH10505668A (en) |
AU (1) | AU3393395A (en) |
CA (1) | CA2198707A1 (en) |
GB (1) | GB9417850D0 (en) |
WO (1) | WO1996007915A1 (en) |
ZA (1) | ZA957376B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9614671D0 (en) * | 1996-07-12 | 1996-09-04 | Imperial College | Predictive test |
EP0979080B9 (en) * | 1997-01-02 | 2012-02-22 | Thomas Jefferson University | A method of modulating an immune response in an infected mammal by transmucosal administration of modulating agent |
-
1994
- 1994-09-02 GB GB9417850A patent/GB9417850D0/en active Pending
-
1995
- 1995-09-01 EP EP95930612A patent/EP0778948A1/en not_active Withdrawn
- 1995-09-01 WO PCT/GB1995/002067 patent/WO1996007915A1/en not_active Application Discontinuation
- 1995-09-01 AU AU33933/95A patent/AU3393395A/en not_active Abandoned
- 1995-09-01 JP JP8509285A patent/JPH10505668A/en active Pending
- 1995-09-01 ZA ZA957376A patent/ZA957376B/en unknown
- 1995-09-01 CA CA002198707A patent/CA2198707A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO9607915A1 * |
Also Published As
Publication number | Publication date |
---|---|
ZA957376B (en) | 1997-03-03 |
AU3393395A (en) | 1996-03-27 |
CA2198707A1 (en) | 1996-03-14 |
JPH10505668A (en) | 1998-06-02 |
WO1996007915A1 (en) | 1996-03-14 |
GB9417850D0 (en) | 1994-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Stevens et al. | Perinatal hepatitis B virus transmission in the United States: prevention by passive-active immunization | |
McDermott et al. | Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination | |
Waters et al. | Loss of the common | |
Wang et al. | Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies | |
Maupas et al. | Immunisation against hepatitis B in man | |
Krogsgaard et al. | The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers | |
Xu et al. | Occult HBV infection in anti-HBs-positive young adults after neonatal HB vaccination | |
Barin et al. | Immune response in neonates to hepatitis B vaccine | |
Varla‐Laftnerioti et al. | HLA‐associated non‐responsiveness to Hepatitis B vaccine | |
Maupas et al. | Hepatitis B vaccine: efficacy in high-risk settings, a two-year study | |
Hollinger et al. | Anti-HBs responses to vaccination with a human hepatitis B vaccine made by recombinant DNA technology in yeast | |
US20170260257A1 (en) | Antibody composition for prevention or treatment of mutant hepatitis b virus infection | |
Heijtink et al. | Co‐occurrence of HBsAg and anti‐HBs: Two consecutive infections or a sign of advanced chronic liver disease? | |
Hsu et al. | Association of HLA-DR14—DR52 with low responsiveness to hepatitis B vaccine in Chinese residents in Taiwan | |
Madalinski et al. | Antibody responses to preS components after immunization of children with low doses of BioHepB | |
Verdon et al. | Absence of association between HLA antigens and chronicity of viral hepatitis in haemodialyzed patients | |
Van Hecke et al. | Hepatitis B virus-specific cytotoxic T lymphocyte responses in patients with acute and chronic hepatitis B virus infection | |
Amirzargar et al. | HLA-DRB1, DQA1 and DQB1 Alleles and Hap-lotypes Frequencies in Iranian Healthy Adult Responders and Non-Responders to Recombi-nant Hepatitis B Vaccine | |
Coursaget et al. | Anti-pre-S2 antibodies in natural hepatitis B virus infection and after immunization | |
Stephan et al. | Modulation of hepatitis B infection by intravenous application of an immunoglobulin preparation that contains antibodies to hepatitis B e and core antigens but not to hepatitis B surface antigen | |
EP0778948A1 (en) | Predictive test for hepatitis-b resistance | |
Goh et al. | Long-term immunogenicity and efficacy of a reduced dose of plasma-based hepatitis B vaccine in young adults. | |
US20010005507A1 (en) | Predictive test for hepatitis-B resistance | |
AU5718199A (en) | Predictive test for hepatitis-B resistance | |
Wakita et al. | Cellular immune responses of peripheral blood mononuclear cells to HBV antigens during chronic and acute HBV infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970317 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19980529 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040504 |